Drugs

UB-421

UB-421

Other Names: mAb dB4, mAb dB4C7 Drug Class: CD4 Attachment Inhibitor Organization: United Biomedical, Inc. Phase of Development: III

(Compound details obtained from United Biomedical, Inc. website,1 ClinicalTrials.gov,2 and Treatment Action Group 2017 Pipeline Report3)

What is UB-421?

What is UB-421?

UB-421 is an investigational drug that is being studied to treat HIV infection.1

UB-421 belongs to a group of HIV drugs called CD4 attachment inhibitors.3 CD4 attachment inhibitors work by attaching to a protein on the surface of the immune cells. The protein is called the CD4 receptor. When UB-421 attaches to the CD4 receptor, HIV cannot attach to, enter, or infect the cell.1 This prevents HIV from multiplying and can reduce the amount of HIV in the body.

To learn about how investigational drugs are tested during clinical trials, read the AIDSinfo What is an Investigational HIV Drug? and HIV/AIDS Clinical Trials fact sheets.

Which clinical trials are studying UB-421?

Which clinical trials are studying UB-421?

Study Name: NCT01668043 
Phase: IIa
Status: This study has been completed.
Location: Taiwan
Purpose: The purpose of this study was to look at 2 different doses of UB-421 in adults with HIV who had never taken HIV medicines before. UB-421 was given without any other HIV medicines (also known as monotherapy). UB-421’s safety and effectiveness in lowering viral load were assessed.4

Study Name: NCT02369146 
Phase: II
Status: This study has been completed.
Location: Taiwan
Purpose: The purpose of this study was to evaluate the safety and effectiveness of 2 different doses of UB-421 monotherapy as a substitute for ART.5,6

Study Name: NCT03164447
Phase: II/III
Status: This study is not yet open for participant recruitment.
Location: Not available.
Purpose: The purpose of this study is to evaluate the efficacy, safety and tolerability of UB-421 when used first with a treatment regimen that is not working, then with optimized background therapy (OBT).

Study Name: NCT03149211 
Phase: III
Status: This study is not yet open for participant recruitment. 
Location: Not available
Purpose: The purpose of this study is to evaluate the safety and effectiveness of UB-421 monotherapy as a substitute for ART.2

For more details on the studies listed above, see the Health Professional version of this drug summary.

What side effects might UB-421 cause?

What side effects might UB-421 cause?

One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of UB-421 listed above.

NCT01668043:
In this Phase IIa study, the most common side effects related to UB-421 were rash and hives. One participant had 2 serious side effects: tonsillitis and rash.4,8

NCT02369146:
In this Phase II study, the most common side effect that was possibly or probably related to UB-421 was mild or moderate skin rash, and it occurred in about 48% of participants. Some participants had increases in esosinophils, which are a type of disease-fighting white blood cell, and some participants had elevated liver enzyme levels.5

Because UB-421 is still being studied, information on possible side effects of the drug is not complete. As testing of UB-421 continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying UB-421?

Where can I get more information about clinical trials studying UB-421?

More information about UB-421-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a clinical trial is right for you. For information, visit NIH Clinical Research Trials and You.

References

References

  1. United Biomedical, Inc. UB-421. http://www.unitedbiomedical.com/Ub-421.htm. Accessed July 20, 2018.
  2. United BioPharma. A Phase III, randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-1 infected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 2, 2017. NLM Identifier: NCT03149211. https://clinicaltrials.gov/ct2/show/NCT03149211. Accessed July 20, 2018.
  3. Frick M, Gaudino A, Harrington M, Horn T. Treatment Action Group. 2017 pipeline report. http://www.pipelinereport.org/sites/default/files/2017%20Pipeline%20Report%20Final.pdf. Accessed July 20, 2018.
  4. United Biomedical. A Phase IIa, open-label, multiple-dose trial to investigate the safety and efficacy of the UB-421 in asymptomatic HIV-1 infected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 1, 2012. NLM Identifier: NCT01668043. https://clinicaltrials.gov/ct2/show/NCT01668043. Accessed July 20, 2018.
  5. United BioPharma. A Phase II, open-label, multiple-dose trial to investigate the safety and efficacy of UB-421 monotherapy in substitution for stable antiretroviral therapy in HIV infected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 5, 2015. NLM Identifier: NCT02369146. https://clinicaltrials.gov/ct2/show/NCT02369146. Accessed July 20, 2018.
  6. United BioPharma. Press release, dated November 26, 2014. United BioPharma completes Phase IIa clinical trial of innovative antibody drug UB-421 for AIDS treatment. http://www.unitedbiopharma.com/eng/page401_15.html. Accessed May 29, 2017.
  7. United BioPharma. A multicenter, randomized, parallel-arm, 24-week study of UB-421 in combination with optimized background therapy (OBT) regimen in patients with multi-drug resistant (MDR) HIV-1 infection.  In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 21, 2017. NLM Identifier: NCT03164447. https://clinicaltrials.gov/ct2/show/NCT03164447. Accessed July 20, 2018.
  8. Wang C-Y, Wong W-W, Tsai H-C, Chen Y-H, Liao M-J, Lynn S. A Phase 2 open-label trial of antibody UB-421 monotherapy as a substitute for HAART. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 13-16, 2017; Seattle, WA. Poster 450LB. http://www.croiconference.org/sites/default/files/posters-2017/450LB_Wong.pdf. Accessed July 20, 2018.

Last Reviewed: July 20, 2018